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Abstract
Background: Retrospective analysis of outcomes of R0 (negative margin) versus R1 (positive margin)
liver resections for colorectal metastases (CLM) in the context of peri-operative chemotherapy.
Methods: All CLM resections between 2000 and 2006 were reviewed. Exclusion criteria included:
macroscopically incomplete (R2) resections, the use of local treatment modalities, the presence of
extra-hepatic disease and no peri-operative chemotherapy. R0/R1 status was based on pathological
examination.
Results: Of 86 eligible patients, 63 (73%) had R0 and 23 (27%) had R1 resections. The two groups were
comparable for the number, size of metastases and type of hepatectomy. The R1 group had more bilobar
CLM (52% versus 24%, P = 0.018). The median follow-up was 3.1 years. Five-year overall and disease-
free survival were 54% and 21% for the R0 group and 49% and 22% for the R1 group (P = 0.55 and
P = 0.39, respectively). An intra-hepatic recurrence was more frequent in the R1 group (52% versus 27%,
P = 0.02) and occurred more frequently at the surgical margin (22% versus 3%, P = 0.01).
Discussion: R1 resections were associated with a higher risk of intra-hepatic and surgical margin
recurrence but did not negatively impact survival suggesting that in the era of efficient chemotherapy, the
risk of an R1 resection should not be considered as a contraindication to surgery.
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Introduction
Resection of colorectal liver metastases (CLM) is the only potential
curative treatment with 37–58% and 22–26% actuarial survival
rates at 5- and 10-years, respectively.1–3 Surgical margin status has
been reported to be a major prognostic factor after a CLM resection
and a R0 resection remains the standard goal in this field.4–6 The
advent of more effective chemotherapy regimens challenged the
1.0-cm dogma of a clear surgical margin leading to the concept of
complete macroscopic removal of all lesions regardless of width.7,8
Furthermore, recent studies have suggested that even R1 resections
were also associated with significant survival.9
In a series of 436 patients operated on for CLM, de Hass et al.9
reported similar overall-survival and recurrence-free survival
rates after a margin-negative (R0) and margin-positive (R1) hepa-
tectomy (so-called R1 resection by necessity).9 Although promis-
ing, these results remain debatable5,6,10,11 as the group of R1
resections received more frequently pre- and/or post-operative
chemotherapy (P < 0.01). These results remained to be confirmed
in a homogenous population of patients in terms of modern
peri-operative chemotherapy.12–16
The aim of this retrospective study was to compare the
oncological outcomes of R0 (margin 1 mm) versus R1
(margin <1 mm) resections for CLM where all patients received
pre- and/or post-operative chemotherapy during a recent
period.*The first two authors contributed equally to the present study.
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Patients and methods
Patients
Between January 2000 and December 2006, 493 patients under-
went a liver resection at a single institution (AP-HP, Henri
Mondor University Hospital, Créteil, France). Among the 153
consecutive patients operated on for CLM, 67 (43.8%) were
excluded from the present study for the following exclusion crite-
ria: (i) incomplete macroscopic resection (R2), (ii) the presence of
concomitant extra-hepatic disease, (iii) the use of local treatment
modalities such as radiofrequency ablation in combination with
surgery, (iv) no pre- and/or post-operative systemic chemo-
therapy. With the approval of the local Institutional Review Board,
86 patients were retrieved from a prospective database and were
eligible for the study. All underwent a liver resection with curative
intent, defined as an attempt to achieve a macroscopically com-
plete resection of all hepatic tumour burdens with a clear macro-
scopic surgical margin.
Disease staging
All patients were staged upon physical examination, as well as the
level of serum carcinoembryonic antigen (CEA), colonoscopy and
multidetector computed tomography (CT) scans of the abdomen,
pelvis and chest. When liver metastases were considered suitable
for curative resection, hepatic magnetic resonance imaging (MRI)
was performed. A response to chemotherapy was evaluated every
four cycles by CT according to the Response Evaluation Criteria in
Solid Tumors (RECIST) criteria.17 This was done during a multi-
disciplinary meeting including liver surgeons, oncologists, radi-
ologists and pathologists.
Surgery
For all patients, timing of the surgery was determined by the
multidisciplinary oncology committee. Segmental resections were
classified as ‘anatomical’ whereas wedge excisions of less than a
segment of liver were classified as ‘non-anatomical’. During the
operation, a complete examination of the liver was performed by
palpation and intra-operative ultrasonography to accurately
determine the number, size and location of the lesions, their rela-
tionship to major vascular structures, and to rule out additional
unknown lesions. A parenchymal transection was performed
using the crush clamp technique or with a Cavi-Pulse Ultrasonic
Surgical Aspirator (CUSATM, Model 200T; Valleylab, Boulder,
CO, USA) under low central venous pressure anaesthesia with an
intermittent Pringle manoeuvre if necessary. Although a 1-cm
margin was the aim of the liver resection, a grossly negative mac-
roscopic margin without tumour exposure was considered
adequate.
Pathological assessment
All liver specimens were addressed fresh to the Department of
Pathology and analysed before and after formalin fixation by a
senior pathologist. All specimens were photographed before and
after being sliced. The diameter of each liver metastasis was
recorded. The surgical resection surface was painted with ink. The
largest cut surface for each metastatic tumour was obtained from
each liver specimen. Each metastatic tumour was embedded in
paraffin, and examined on haematoxylin and eosin-stained slides
of 3–5 mm. R0 and R1 resections were reviewed by a single
pathologist (M.L.A.) and defined by the absence (tumour-free
margin1 mm for all resected lesions) or presence (tumour-free
margin <1 mm for any resected lesion) of a microscopic tumour
at the resection margins, respectively.
Radiological assessment of intra-hepatic recurrence
CT scans of all patients who developed intra-hepatic recurrence
were reviewed by two senior radiologists (A.L. and L.B.) to assess
whether recurrence occurred at the surgical margin or elsewhere
in the liver.
Follow-up
Patients were followed by physical examination, CEA testing and
CT scans of the abdomen, pelvis and chest every 4–6 months. No
patient was lost to follow-up.
Study end-points
The primary end-point of the study was to compare long-term
oncological outcomes of R0 (margin 1 mm) and R1 (margin
<1 mm) resections for CLM. The secondary end points were to
assess the pattern of recurrences with particular focus on intra-
hepatic recurrences between the two groups.
Statistical analysis
Patients were identified from the institution’s prospectively main-
tained database and analysed retrospectively. Results were
expressed as median and first and third quartiles (Q1 to Q3) or
counts and percentages. Patients with CLM resection margins of
1 mm constituted the R0 group and those with margins <1 mm
the R1 group. Patient characteristics in the two groups were com-
pared using Fisher’s exact test for categorical variables and Wil-
coxon’s test for continuous variables. Overall survival, hepatic
recurrence-free survival and recurrence-free survival were deter-
mined using the Kaplan–Meier method. Differences in survival
between the two groups were estimated using the Cox propor-
tional cause-specific hazards model and expressed as hazard ratios
(HR) with 95% confidence intervals (CI). A two-sided P-value of
0.05 was considered significant. All analyses were performed using
R 2.10.1 statistical software (The R foundation of Statistical Com-
puting, Vienna, Austria).
Results
Study population
During the study period, 153 patients underwent resection
CLM. Sixty-seven (43.8%) patients were excluded for R2 resec-
tion (n = 5), extrahepatic hepatic disease (localized resected car-
cinomatosis, n = 6, hepatic pedicle lymph node, n = 12, lung
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metastases, n = 8), or no chemotherapy (n = 36). The remaining 86
patients (56.2%) operated on for CLM fulfilled the inclusion cri-
teria. Among them, 63 (73%) had R0 and 23 (27%) had R1 liver
resections. Patient demographics and tumour characteristics are
shown in Table 1.
Pre- and/or post-operative chemotherapy
All included patients received both pre- and/or post-operative
systemic chemotherapy (Table 1) with the following regimens:
LV5FU2 (n = 5, 6%), FOLFOX (n = 53, 62%), FOLFIRI (n = 12,
14%) and FOLFOX or FOLFIRI in association with Bevacizumab
(n = 16, 19%). Most patients received pre- and post-operative
systemic chemotherapy (55/86, 63.9%). Although the median
number of pre-operative lines of chemotherapy was similar
between the two groups, patients in the R1 group received signifi-
cantly more courses of pre-operative chemotherapy compared to
those in the R0 group (P = 0.039).
Operative data
Among the 86 patients, 5 (6%) underwent a fully laparoscopic
liver resection (all R0) and 6 (7%) additional patients underwent
a laparoscopic hand-assisted hepatectomy (R0 n = 5, R1 n = 1).
A major hepatectomy was carried out in 57 (66.3%) patients
with no difference between the two groups (Table 2). Although
a trend towards slightly higher rates of non- anatomical resec-
tions was observed in the R1 group [2 (8.7%) versus 4 (6.5%)
patients in the R0 group], this difference was not statistically
different.
Table 1 Patient and tumour characteristics
Variable Total
(n = 86)
R0 group
(n = 63)
R1 group
(n = 23)
P
Patients
Age, median (Q1–Q3), years 62 (56–72) 63 (56–71) 58 (56–73) 0.530
Gender: male/female 55/31 43/20 12/11 0.210
Primary tumour (numbers)
Colon ectum 63/23 46/17 17/6 >0.9
T1-T2/T3-T4 6/74 4/55 2/19 0.542
N0/N+ 18/60 12/46 6/14 0.601
Liver metastases
Number of nodules, median (Q1–Q3) 2 (1–3) 2 (1–3) 3 (1–3.5) 0.130
<3 nodules, n (%) 53 (62%) 42 (67%) 11 0.140
Bilobar, n (%) 27 (31%) 15 (24%) 12 0.018
Maximum diameter, mm, n (Q1–Q3) 36 (25–52.5) 36 (24–59) 36.5 (30–50) 0.770
Maximum diameter < 50 mm, n (%) 55 (65.5%) 40 (64.5%) 15 0.800
Synchronous, n (%) 55 (64%) 38 (60%) 17 0.310
Pre-operative CEA > 200 (ng/ml), n (%) 30 (35%) 21 (33%) 9 0.619
Chemotherapy
Pre- and post-operative, n (%) 55 (63.9%) 39 (61.9%) 16 0.615
Post-operative only, n (%) 15 (17.4%) 9 (14.2%) 6 0.214
Combined post-operative 70 (81.4%) 48 (76.2%) 22 0.058
Pre-operative only, n (%) 16 (18.6%) 15 (23.8%) 1 0.058
6 pre-operative cycles, n (%) 29 (34%) 17 (27%) 12 0.039
Number of pre-operative lines, median (Q1–Q3) 1 (1–2) 1 (1–1) 2 (1–3) 0.562
CEA, carcinoembryonic antigen; Q1–Q3, first and third quartiles.
Table 2 Operative data
Variable (n, %) Total
(n = 86)
R0 group
(n = 63)
R1 group
(n = 23)
P
Major hepatectomy 57 (66.3%) 41 (65.1%) 16 0.800
Combined anatomical and non-anatomical resection 23 (26.7%) 13 (21%) 10 0.053
Non-anatomical resection only 6 (7.1%) 4 (6.5%) 2 0.094
Combined hepatectomy and primary tumour resection 18 (20.9%) 13 (20.6%) 5 >0.9
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Long-term outcomes
The median follow-up for the entire study population was 3.1
years (range: 2.0–4.3). Overall survival rates at 1-, 3- and 5-years
were 98%, 74% and 54% in the R0 group and 96%, 81% and 49%
in the R1 group, respectively [HR = 1.27 (0.58–2.76), P = 0.55]
(Fig. 1). During the follow-up, 42 patients (66.7%) in the R0
group and 16 patients (69.6%) in the R1 group had recurrence
(P = 0.600) (Table 3). Disease-free survival rates at 1-, 3-, and 5-
years were 73%, 29% and 21% in the R0 group and 70%, 22% and
22% in the R1 group, respectively [HR = 0.28 (0.73–2.25), P =
0.39] (Fig. 2). Intra-hepatic recurrence was significantly (P =
0.029) more frequent in the R1 group (52%) compared with the
R0 group (27%). More specifically, hepatic recurrence-free sur-
vival at 1-, 3-, and 5-years was 85%, 72% and 67% in the R0 group
and 74%, 44% and 44% in the R1 group, respectively [HR = 2.39
(1.14–5.03), P = 0.021] (Fig. 3). According to the location of intra-
hepatic recurrence, significantly more recurrences occurred at the
surgical margin after R1 compared with a R0 resection (34.7%
versus 6% respectively, P = 0.006).
Discussion
The present study is one of the first to compare the oncological
outcomes of R0 and R1 resections of CLM in patients who
received peri-operative systemic chemotherapy. The present study
shows that R1 resections: (i) occur more frequently in patients
with bilobar disease, (ii) are associated with a higher risk of intra-
hepatic recurrence, (iii) are associated with more frequent surgical
margin recurrences, and (iv) do not negatively impact disease-free
and overall survival rates. These results suggest that in the era of
efficient chemotherapy, the risk of an R1 resection should not be
considered a contraindication to surgery with curative intent, as
R1 patients had a satisfactory 5-years survival rate of 49% and half
the patients did not have intra-hepatic recurrence.
In the present series, 27% of patients operated with a curative
intent underwent an R1 hepatectomy for CLM, consistent with
the reported range of 5% to 46%.8,12,18 In the current series, bilobar
disease was associated with an increased risk of a R1 resection. The
presence of multiple, large, bilateral tumours and tumours located
centrally or close to a major vessel are the most common factors
reported to be associated with an increased risk of R1 resection.8,18
Although some studies have suggested that intra-operative factors
such as non-anatomic resections and extended resections may be
associated with a higher likelihood of an R1 resection,9,18–20 other
investigators have found this not to be the case.21 In the present
series, anatomical resections were not superior to non-anatomic
resections or combined anatomic and non-anatomic resections in
terms of surgical margin clearance.
Cumulative data suggest that a R1 resection is associated with
an increased risk of hepatic recurrence, both distant to or at the
surgical margin. Whereas recurrence in the liver was reported to
occur in 14–38% of patients after a R0 resection, the rate of liver
recurrence has been noted to be as high as 22–78% after R1
resections.8,12 Similarly, in the present series, intra-hepatic recur-
rence were significantly more frequent in the R1 group (52%)
compared with the R0 group (27%, P = 0.029) with a 5-year
hepatic recurrence-free survival of 67% in group R0 and 44% in
group R1 (P = 0.021). As reported by others,6,10,11 when subdivided
according to location of hepatic recurrence, significantly more
recurrences occurred at the surgical margin after R1 compared
with R0 resections in this study (21.7% versus 3.1% respectively, P
= 0.01). This is probably the result of histological micrometastases
found in the liver parenchyma surrounding CLM within 5 mm of
the tumour border22,23 which have not been sterilized by chemo-
therapy24 or destroyed by surgical cautery. In contrast, de Hass
et al. 9 reported similar recurrence rates at the surgical margin
after a R1 resection compared with a R0 resection (9% versus 8%,
P = 0.72). In the current study, the 3.1% rate of margin recurrence
after a R0 resection is in the reported range of 3% to 8%.6,9–11
All but one previous study9 have demonstrated that R1 resec-
tions negatively impact long-term outcome with 5-year overall
survival rates ranging from 0–20% compared with the 37–64% for
R0 resections.6,12,18 In a series of 436 patients operated on for CLM,
de Hass et al.9 reported that patients undergoing a R1 versus a R0
resection had similar 5-year survival rates (57% versus 61%, P =
0.27). In the latter series, R1 patients received significantly more
chemotherapy before and after resection compared with their R0
counterparts. Within the present study, R1 patients received
slightly more combined chemotherapy but the difference did not
reach statistical significance. Therefore, in a homogeneous popu-
lation regarding chemotherapy administration, it has been shown
that 5-year overall survival rates were not different after a R0 and
R1 hepatectomy (54% versus 49%). Tanaka et al.12 demonstrated
in a series of 310 patients, that the R1 resection group had poorer
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Figure 1 Overall survival after a R0 (n = 63) and R1 (n = 23) liver
resection for colorectal metastases. HR; hazard ratio
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overall survival than the R0 resection group. However, in this
series, when patients were stratified according to their initial
resectability, this negative impact of R1 resection was not observed
in patients with initially unresectable or marginally resectable
metastases, especially those with a favourable response to pre-
hepatectomy chemotherapy.12 Together with the present results
(17% of patients with initially unresectable disease in the R1
group) and those from de Hass et al.,9 the negative prognostic
impact of R1 CLM resections should be reconsidered given the
good survival rates in patients receiving effective peri-operative
chemotherapy.8 The gap between overall- and disease-free sur-
vival rates within the current series confirms the major impor-
tance and efficacy of chemotherapy. The patients in the present
study were treated by efficient chemotherapy regimens (FOLFOX
or FOLFIRI) associated with targeted agents in 19% of them,
corresponding to most recent patients in the series. These regi-
mens have been demonstrated to improve both response rates and
survival in the colorectal metastatic setting.25–28
The limitations of the present study were that a limited number
of patients were analysed, the retrospective analysis of the data
and a relatively limited follow-up that ended the first of January
2010. The few patients remaining at the end of the follow-up
could be a limitation to the power analysis of the study.
In spite of the limited number of patient analysed, the present
findings suggest a R0 resection should remain the gold standard
recommendations for patients operated on for CLM. However, R1
resection margins should not be considered a contraindication to
surgery provided complete macroscopic removal of all metastatic
lesions and administration of effective peri-operative chemo-
therapy. In spite of a higher risk of intra-hepatic and surgical
Table 3 Long-term outcome
Variable Total
(n = 86)
R0 group
(n = 63)
R1 group
(n = 23)
P
Follow-up, median years (Q1–Q3) 3.1 (2.0–4.3) 3.1 (2–4.5) 2.9 (1.9–4) 0.584
Recurrence 58 (67.4%) 42 (66.7%) 16 0.600
Extra-hepatic 29 (33.7%) 25 (39.7%) 4 0.072
Intra-hepatic 13 (15.1%) 6 (9.5%) 7 0.036
Both 16 (18.6%) 11 (17.5%) 5 0.760
Intra-hepatic recurrence location
Overall intra-hepatic recurrence 29 (33.7%) 17 (27%) 12 0.029
At surgical margin 7 (8.1%) 2 (3.1%) 5 0.013
Curable 16 (55.2%) 9 (52.9%) 7 0.770
Repeat hepatectomy 10 (11.6%) 8 (47%) 2 0.894
Ablation 6 (20.7%) 1 (5.9%) 5 0.005
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margin recurrences, R1 patients have a satisfactory 5-years survival
rate of 49%. Not resecting them would lead to propose chemo-
therapy as the only alternative with a lower survival expectancy.
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